Payment overview · 2025
General Payments
$2,163.34
105 reported records · 26 companies
Healthcare provider profile · identity verified
Mark Frederick Cohen, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LANCASTER, PA · NPI 1164434015
Verified facts
What the public records show
CMS Open Payments records show Mark Frederick Cohen, D.O. received $2,163.34 in general payments during 2025 across 105 reported records.
Novo Nordisk Inc accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rexulti, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 418 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $285.76 | 13.2% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $172.08 | 8.0% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $161.16 | 7.5% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $153.75 | 7.1% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $151.67 | 7.0% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.02 | 6.5% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $123.90 | 5.7% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $122.33 | 5.7% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $111.29 | 5.1% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.10 | 4.7% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $100.62 | 4.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.57 | 4.6% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $62.38 | 2.9% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$55.06 | 2.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.03 | 2.0% | 2 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $40.21 | 1.9% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $34.22 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.66 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.08 | 1.2% | 1 | 2025 |
| Nalu Medical, Inc. | Unresolved — no canonical attribution shown | $25.74 | 1.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $23.33 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.13 | 1.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.02 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.45 | 0.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.07 | 0.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $15.71 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,163.34 | 105 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $312.83 | 18 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $196.01 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $172.08 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $153.75 | 8 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $123.90 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $111.29 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $107.30 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $107.30 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.03 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $100.62 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.75 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $62.38 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $61.56 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.33 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.33 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.70 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.85 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $44.24 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.03 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.54 | 2 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $40.21 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $34.22 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $33.72 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $33.72 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $33.72 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.66 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.08 | 1 | 2025 |
Source payment records
|
|||||
| Nalu Neurostimulation System Normalized: nalu neurostimulation system |
Device | Nalu Medical, Inc. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 185 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
185 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 22 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
185 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
418 | 23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1395 | 52 |
| Lisinopril | Lisinopril | 992 | 62 |
| Gabapentin | Gabapentin | 942 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 920 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 769 | 45 |
| Carvedilol | Carvedilol | 760 | 45 |
| Sertraline Hcl | Sertraline Hcl | 754 | 21 |
| Furosemide | Furosemide | 741 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 736 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 689 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 611 | 25 |
| Trazodone Hcl | Trazodone Hcl | 554 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 550 | 24 |
| Omeprazole | Omeprazole | 467 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 464 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 446 | 24 |
| Potassium Chloride | Potassium Chloride | 440 | 25 |
| Eliquis | Apixaban | 418 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 405 | 21 |
| Simvastatin | Simvastatin | 390 | 41 |
| Donepezil Hcl | Donepezil Hcl | 382 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 368 | 36 |
| Metformin Hcl | Metformin Hcl | 333 | 20 |
| Losartan Potassium | Losartan Potassium | 329 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 311 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 252 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 226 | 14 |
| Olanzapine | Olanzapine | 223 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 20 |
| Buspirone Hcl | Buspirone Hcl | 206 | suppressed |
| Finasteride | Finasteride | 202 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 198 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 195 | 17 |
| Rexulti | Brexpiprazole | 185 | 18 |
| Spironolactone | Spironolactone | 185 | 16 |
| Xarelto | Rivaroxaban | 177 | 15 |
| Aripiprazole | Aripiprazole | 174 | suppressed |
| Bumetanide | Bumetanide | 172 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 169 | suppressed |
| Meloxicam | Meloxicam | 167 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 162 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 159 | suppressed |
| Levetiracetam | Levetiracetam | 141 | suppressed |
| Sucralfate | Sucralfate | 139 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 137 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 135 | 18 |
| Ozempic | Semaglutide | 131 | 22 |
| Bupropion Xl | Bupropion Hcl | 122 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 117 | suppressed |
| Digoxin | Digoxin | 113 | suppressed |
| Prednisone | Prednisone | 106 | 14 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 105 | suppressed |
| Risperidone | Risperidone | 102 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 92 | suppressed |
| Jardiance | Empagliflozin | 90 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 89 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 87 | suppressed |
| Memantine Hcl | Memantine Hcl | 85 | suppressed |
| Topiramate | Topiramate | 84 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 79 | suppressed |
| Famotidine | Famotidine | 78 | suppressed |
| Tradjenta | Linagliptin | 77 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 76 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 71 | 15 |
| Nifedipine Er | Nifedipine | 71 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 70 | suppressed |
| Mirtazapine | Mirtazapine | 68 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 66 | suppressed |
| Allopurinol | Allopurinol | 65 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 65 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 63 | suppressed |
| Lansoprazole | Lansoprazole | 61 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 60 | suppressed |
| Vraylar | Cariprazine Hcl | 60 | suppressed |
| Torsemide | Torsemide | 59 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 57 | 13 |
| Lamotrigine | Lamotrigine | 56 | suppressed |
| Anastrozole | Anastrozole | 55 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 54 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 54 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 53 | suppressed |
| Latuda | Lurasidone Hcl | 53 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 53 | suppressed |
| Movantik | Naloxegol Oxalate | 53 | suppressed |
| Paliperidone Er | Paliperidone | 53 | suppressed |
| Repaglinide | Repaglinide | 53 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 50 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 49 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 42 |
| Linzess | Linaclotide | 45 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 39 |
| Gemtesa | Vibegron | 43 | suppressed |
| Buprenorphine | Buprenorphine | 42 | suppressed |
| Lorazepam | Lorazepam | 42 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 40 | suppressed |
| Latanoprost | Latanoprost | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 14 |
| Valsartan | Valsartan | 40 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 39 | suppressed |
| Nyamyc | Nystatin | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 37 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 14 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Meropenem | Meropenem | 28 | suppressed |
| Phenazopyridine Hcl | Phenazopyridine Hcl | 28 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Nystatin | Nystatin | 27 | 17 |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 16 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Leflunomide | Leflunomide | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 23 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 22 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | 16 |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Invega Sustenna | Paliperidone Palmitate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Calcipotriene | Calcipotriene | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,163.34 · 105 records | Novo Nordisk Inc | ABRYSVO, AFREZZA, AIRSUPRA, AUSTEDO XR, Auvelity, BEYFORTUS, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, FANAPT, FARXIGA, IBSRELA, INGREZZA, JARDIANCE, Kerendia, LYBALVI, MOUNJARO, NURTEC ODT, Nalu Neurostimulation System, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SX-ONE MICROKNIFE, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error